Xylyx Bio, Inc.
Publicly observedBrooklyn, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Brooklyn | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Xylyx Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | N2N9KL2Y52X1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant8 Sept 2025Publicly observed
NIH SBIR/STTR award: Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation
USD 1,483,340.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant8 Sept 2025Publicly observed
NIH SBIR/STTR award: Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation
USD 1,515,926.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
USD 956,566.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
USD 967,715.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant6 Jun 2024Publicly observed
NIH SBIR/STTR award: Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
USD 1,003,395.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant6 Jun 2024Publicly observed
NIH SBIR/STTR award: Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
USD 966,420.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.